NattoPharma Introducing the first and only full-spectrum Vitamin K2 that provides MK-6, 7, 8 & 9
OSLO, NORWAY and METUCHEN, NJ (September 21, 2017) – NattoPharma further strengthens its reputation as the most comprehensive Vitamin K2 supplier by introducing a breakthrough unlike anything on the market: MenaQ7® Full Spectrum K2. This latest innovation is the result of a proprietary technological breakthrough, creating a Vitamin K2 that provides menaquinones (MK) 6, 7, 8 and 9, a range of isomers vital for cardiovascular health.
“NattoPharma has driven the creation of the Vitamin K2 market, sponsoring the important research validating the importance of K2 for human health, and this work has shaped the MenaQ7 brand,” says NattoPharma Chief Medical Officer Dr. Hogne Vik. “The important epidemiological studies that led us to our ground-breaking human clinical research used fermented cheese as the source of Vitamin K2, which led us to create MenaQ7 Full Spectrum.”
According to researchers closely linked to these epidemiological studies1-3: “Vitamin K is a fat-soluble vitamin that plays and unequivocal role in the activation of Gla-proteins. Although all K-vitamins have the same function, they differ in bioavailability and bioactivity.
“The Rotterdam and Prospect studies have shown that food-derived vitamin K (such as from cheeses) improves long-term cardiovascular health outcomes because it more specifically delivers the long-chain menaquinones MK-6, 7, 8 and 9.”
“While fermented cheeses are the best dietary source of menaquinones in the West, most will not be able to consume enough to obtain optimal amounts of Vitamin K2, nor is cheese a practical source for extracting the menaquinones,” adds Dr. Vik. “To that end, NattoPharma has once again broken the mold and offers to the market a raw material that delivers the range of menaquinones found in foods.”
The first and only Vitamin K2 to deliver to deliver a gamut of menaquinone isomers, MenaQ7® Full Spectrum is naturally fermented using chickpea protein, offering an all-trans Vitamin K2 that is free from gluten, soy and all-known allergens, and is suitable for vegans and vegetarians. MenaQ7® Full Spectrum provides the vital menaquinone isomers MK-6, 7, 8 and 9 for optimal and maximal delivery of vitamin K2 with respect to absorption, half-life and biological activity.
“NattoPharma has once again created a raw material that speaks directly the natural dietary supplement consumer, who is drawn to comprehensive nutritional sources,” says Daniel Rosenbaum, NattoPharma CEO. “We welcome the opportunity to meet with companies at this year’s SupplySide West to officially launch this market-changing innovation.”
MenaQ7® Full Spectrum Vitamin K2 will be centrepiece of NattoPharma’s SupplySide West booth P115.
1 Geleijnse JM, Vermeer C, Grobbee DE, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr. 2004;134:3100-5.
2 Beulens JW, Bots ML, Atsma F, et al. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis. 2009;203:489-93.
3 Gast GC, de Roos NM, Sluijs I, et al. A high menaquinone intake reduces the incidence of coronary heart disease. Nutr Metab Cardiovasc Dis. 2009;19:504-10.
# # #
About NattoPharma and MenaQ7®
NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Metuchen, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com.
For more information, please contact:
Kate Quackenbush, Director of Communications
NattoPharma USA, Inc.